David Cutter

Clinical Oncologist at Oxford Cancer Centre and Associate Professor at the University of Oxford.
@ChelseaFC fan. Opinions are mine.

[GLOW: Global nLPHL One Working Group @glow_nlphl]

Our @glow_nlphl lead Dr. @JamieFlerlage spoke about the GLOW multicenter study of radiation therapy outcomes for Stage IA NLPHL which she presented at #18ICML for @VJHemOnc. #lymsm #NLPHLsm
https://t.co/XKjBaPeXgs

[Aisling Barrett @ABarrettHaem]

If you’re at #ICML2025 come by my poster 1230-1300. We examine survival by anthracycline use in older cHL patients. TLDR: use anthracycline if at all possible! @DavidJCutter @graham74GC

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

View the latest NNHLA Quarterly Data Dashboard here: https://t.co/AcFnYBAsyI
@HQIP @JillStoddart @lymphomahub @LLSusa @LymphomaAction @lymphoma @DavidJCutter @NHSEngland @AnthonyNolan @bloodcancer_uk @BloodCancer_Res
#data #NHL #Cancer

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

📢Our latest newsletter provides updates on: State of the Nation reporting, our Quarterly Clinical Performance Indicator report, the recent @NATCAN_news webinar & details of the latest report from @bloodcancer_uk 📰 https://t.co/lo0PfPEWyB @HQIP @LymphomaAction @Ed_Pinches #NHL

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

Out this week, this new publication explores how the distribution of trial site locations, may lead to disparities in patient representation in clinical trials. https://t.co/a8esshkOSo @DavidJCutter @LymphomaAction @bloodcancer_uk @NATCAN_news @WileyGlobal @NHSEngland @HQIP

[Aisling Barrett @ABarrettHaem]

Having learned every @BritSocHaem guideline off by heart for my FRCPath, it was very exciting to have been afforded the opportunity to lead an amazing group of co-authors for our GPP regarding bleomycin use in Hodgkin Lymphoma- published today!

https://t.co/1V7n3BqNcc

[Luis Moreno Sánchez @radioncoluis]

Moving beyond mean heart dose: The importance of cardiac substructures in radiation therapy toxicity.
https://t.co/C9lWKbEIW4

[Sophie Sweeting @lymphoma_soph]

The #UKLRG meeting offers opportunities to ask questions, debate issues of interest in clinical practice, hear updates on UK #clinicaltrials and review advances in #lymphoma #radiotherapy techniques. Join us in London 27 Jan: https://t.co/SFwNMhvQvj @PattyDiezH @GeorgeMikhaeel

[Graham Collins @graham74GC]

Steve Ansell highlighting late effects of our treatment. No ‘safe dose’ of dox with respect to cardiac toxicity. Good data for dexrazoxane cardio protection with no evidence of ‘tumour protection’. #ISHL13 #lymsm

[Ingrid Glimelius @glimelius]

Abscopal effect does exist in #Hodgkin lymphoma when RT 20Gy is given to PD-1 treated patiens. New distant responses seen outside RT fields. Pembro-RT an option in R/R HL with limited disease #ISHL13 #lymsm dr Christian Bauses. Also safe with RT with low doses! AERN trial !

[Aisling Barrett @ABarrettHaem]

Thanks to Rajana Advani for including our data in the Best of #ISHL13 session. What a phenomenal three days- so much exciting science and practice-changing trial data, and so many new friends made with exciting future collaboration potential.

[Graham Collins @graham74GC]

Great presentation by @ABarrettHaem on the NHSE dataset of older pts with Hodgkin lymphoma. ABVD assoc with best outcomes but of course used in fitter pts. Profound impact of age, PS, comorbidities in this age group. #ISHL13 #lymsm

[Graham Collins @graham74GC]

Fascinating - the hospital at which a patient with Hodgkin lymphoma is treated in England has more effect on the variation in radiotherapy usage than sex of the patient. Suggests standardisation of approach is not yet achieved! #ISHL13 #lymsm. @DavidJCutter @DavidAdrwJones

[Aisling Barrett @ABarrettHaem]

Excited to be here at #ISHL13 , come along Sunday at 3pm for my talk about our registry analysis @DavidJCutter and swing by our posters regarding translational analysis of the ANIMATE study and our data collection project HoOP @graham74GC #hodgkinlymphoma

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

We promised you something exciting was coming... Our first quarterly report which includes clinical performance indicators & is presented on a new,highly interactive dashboard! 💥 https://t.co/85yaGi2WK4
@HQIP @LymphomaAction @bloodcancer_uk @DavidJCutter @KateWalkerLon #NHL

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

Watch this space! 👀Our latest NNHLA quarterly report is out tomorrow. We won't spoil the surprise, but we've been working on some changes and this time something is different!..... 🤫🏥📊🔎 @HQIP @JillStoddart @bloodcancer_uk @LymphomaAction @BritSocHaem @DavidJCutter

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

📢💥It's here! We are delighted to share our first State of the Nation report; along with a number of supplementary materials. Our thanks to everyone involved in its development. https://t.co/ZuCdSUPP71
@HQIP @LymphomaAction @bloodcancer_uk @DavidJCutter @KateWalkerLon

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

Exciting news! ⭐️The first NNHLA State of the Nation report is out tomorrow! Check this space or the @NATCAN_news webpages for details https://t.co/zpBEWO8Vta #BCAM
@LymphomaAction @bloodcancer_uk @LLSusa @AnthonyNolan @HQIP @NHSEngland @DavidJCutter @macmillancancer @MJAhearne

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

The NNHLA Quality Improvement Plan has landed! The plan sets out:
⭐️5 QI goals
⭐️11 performance indicators
Read the full report here https://t.co/jI6in7K2wR
@LymphomaAction @LLSusa @bloodcancer_uk @BritSocHaem @AnthonyNolan @HQIP @JillStoddart @DavidJCutter @KateWalkerLon

[National Non-Hodgkin Lymphoma Audit (NNHLA) @NNHLA_NATCAN]

We are delighted to share a short blog which has been prepared by our Patient and Public Involvement Chair, Frank Burroughs. Please do take a look. https://t.co/QngkYmTIyI #BCAM
@NATCAN_news @LymphomaAction @bloodcancer_uk @BloodCancerA @BritSocHaem @DavidJCutter @HQIP